---
id: 127
title: Neisseria meningitidis (Meningococcus)
category: organisms
subcategory: gram_negative_cocci
tags: [meningococcus, meningitis, meningococcemia, ceftriaxone, rifampin, prophylaxis]
difficulty: medium
---

## Question

How is meningococcal disease managed? Use the **"Ceftriaxone + Close Contact Prophylaxis (Rifampin or Ciprofloxacin)"** framework.

## Answer

### ***Neisseria meningitidis* Overview:**

**Clinical Syndromes:**
- **Meningococcemia** (bacteremia ± purpura fulminans)
- **Meningitis**
- **Meningococcemia + meningitis** (most common presentation)

**Presentation:**
- **Rapid onset** (hours)
- **Fever, headache, meningismus**
- **Petechial/purpuric rash** (40-60% of cases) - **pathognomonic**
- **Shock** (Waterhouse-Friderichsen syndrome = adrenal hemorrhage)

### **Treatment:**

**Empiric (before susceptibilities):**
- **Ceftriaxone 2g IV q12h** OR **cefotaxime 2g IV q4-6h**
- **+ Vancomycin** (if cannot rule out pneumococcus)
- **+ Dexamethasone 10mg IV q6h × 4 days** (if bacterial meningitis suspected)

**Definitive (once *N. meningitidis* identified):**
- **Ceftriaxone 2g IV q12h** OR **penicillin G 4 million units IV q4h** (if penicillin-susceptible)
- **Duration: 5-7 days**

**Alternative (if β-lactam allergy):**
- **Chloramphenicol 1g IV q6h** OR **moxifloxacin 400mg IV daily**

### **Post-Exposure Prophylaxis (PEP):**

**Indications (Close Contacts):**
- **Household members**
- **Daycare contacts**
- **Direct exposure to secretions** (kissing, sharing drinks/utensils, mouth-to-mouth resuscitation, intubation)
- **Airline passengers** seated directly next to index case (flights >8 hours)

**Regimens:**
- **Rifampin** 600mg PO BID × 2 days (adults) OR 10 mg/kg BID × 2 days (children)
- **Ciprofloxacin** 500mg PO × 1 dose (adults only)
- **Ceftriaxone** 250mg IM × 1 dose (preferred in pregnancy)
- **Azithromycin** 500mg PO × 1 dose (alternative)

**Timing:**
- **Ideally within 24 hours** (effective up to 14 days after exposure)

**Healthcare Workers:**
- **Only if direct exposure** to respiratory secretions (intubation, mouth-to-mouth, unprotected suctioning)
- **Standard precautions sufficient** for routine care

## Key Points

### **Serogroups:**
- **B, C, W, Y** most common in US
- **A, B, C, W, Y, X** globally
- **Serogroup B:** Leading cause in infants/young adults in US (no polysaccharide vaccine, protein-based vaccines available)

### **Vaccines:**

**MenACWY (Conjugate):**
- **Routine:** Age 11-12 years + booster at age 16
- **High-risk:** Asplenia, complement deficiency, HIV, college freshmen in dorms, travelers to endemic areas (sub-Saharan Africa "meningitis belt"), microbiologists

**MenB (Protein-Based):**
- **Not routine** (consider for age 16-23, college students, outbreaks)
- **Mandatory:** Asplenia, complement deficiency, outbreaks

**MenACWY-D (Polysaccharide):**
- Older vaccine, less effective (not routinely used, replaced by conjugate)

### **Complement Deficiency:**
- **Major risk factor** for invasive meningococcal disease
- **Deficiency in terminal complement (C5-C9):** 7,000-10,000× increased risk
- **Eculizumab (C5 inhibitor):** Increases risk 2,000×
- **Screen if:** Recurrent *Neisseria* infections (meningococcus, gonococcus)

### **Purpura Fulminans:**
- **Extensive purpura**, **DIC**, **shock**
- **Waterhouse-Friderichsen syndrome:** Bilateral adrenal hemorrhage (hypotension, adrenal crisis)
- **High mortality** (40-50% if purpura fulminans)

### **Clinical Pearls:**
- **Ceftriaxone 2g IV q12h × 5-7 days** (meningococcal meningitis)
- **Petechial/purpuric rash** = meningococcemia (pathognomonic)
- **Close contact prophylaxis:** Rifampin 600mg BID × 2 days OR ciprofloxacin 500mg × 1
- **Vaccinate:** MenACWY (age 11-12 + 16), MenB (high-risk, college)
- **Complement deficiency:** Screen if recurrent *Neisseria* infections
- **PEP within 24 hours** (close contacts, healthcare workers with direct secretion exposure)

## Sources

- [CDC: Meningococcal Disease Guidelines 2024]
- [IDSA: Bacterial Meningitis Guidelines 2023]

## Media

N/A
